Cefonicid

ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Cefonicid is an ofm drug catalogued in DrugCentral. DrugCentral lists 5 molecular targets, including MMP9, PTGS2 and SSTR4. Recorded indications include Bacterial infection due to Klebsiella pneumoniae, Bacterial septicemia, Escherichia coli urinary tract infection and Haemophilus influenzae pneumonia.

• Approval status: ofm.
• Molecular targets: MMP9, PTGS2, SSTR4 and pbpA (5 listed in DrugCentral).
• Indications: Bacterial infection due to Klebsiella pneumoniae, Bacterial septicemia, Escherichia coli urinary tract infection, Haemophilus influenzae pneumonia and Infection due to Staphylococcus aureus and others.
• ATC code: J01DC06 (Second-generation cephalosporins).
• Molecular formula: C18H18N6O8S3; molecular weight 542.56 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (25)

• Bacterial infection due to Klebsiella pneumoniae
• Bacterial septicemia
• Escherichia coli urinary tract infection
• Haemophilus influenzae pneumonia
• Infection due to Staphylococcus aureus
• Infection of bone
• Infection of skin AND/OR subcutaneous tissue
• Infectious disorder of joint
• Klebsiella cystitis
• Lower respiratory tract infection
• Morganella Morganii Urinary Tract Infection
• Osteomyelitis due to Staphylococcus aureus
• Pneumonia
• Pneumonia due to Escherichia coli
• Pneumonia due to Streptococcus
• Prevention of Perioperative Infection
• Prosthetic Arthroplasty Infection Prevention
• Proteus urinary tract infection
• Providencia Urinary Tract Infection
• Septicemia due to Escherichia coli
• Skin and Skin Structure Streptococcus Agalactiae Infection
• Staphylococcus Epidermidis Skin and Skin Structure Infection
• Streptococcal septicemia
• Streptococcus pyogenes infection
• Urinary tract infectious disease

Mechanism & targets

Molecular targets (5)

Target	Gene	Action	Activity
Matrix metalloproteinase-9	MMP9	unknown	IC50 5.04
Prostaglandin G/H synthase 2	PTGS2	unknown	IC50 4.48
Somatostatin receptor type 4	SSTR4	unknown	IC50 4.24
Penicillin-binding protein 1A	pbpA	unknown	—
Bacterial penicillin-binding protein	mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
—	FDA	—	GLAXOSMITHKLINE

ATC classification

ATC code	Therapeutic hierarchy
J01DC06	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Second-generation cephalosporins

Chemical structure

• Molecular formula: C₁₈H₁₈N₆O₈S₃
• Molecular weight: 542.56 g/mol
• CAS number: 61270-58-4
• InChIKey: DYAIAHUQIPBDIP-AXAPSJFSSA-N
• PubChem CID: 43594

O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cefonicid used for?

DrugCentral lists the following indications for Cefonicid: Bacterial infection due to Klebsiella pneumoniae, Bacterial septicemia, Escherichia coli urinary tract infection, Haemophilus influenzae pneumonia, Infection due to Staphylococcus aureus, Infection of bone, Infection of skin AND/OR subcutaneous tissue and Infectious disorder of joint and others.

How does Cefonicid work?

Its molecular targets in DrugCentral include MMP9, PTGS2, SSTR4 and pbpA.

What is the chemical formula of Cefonicid?

Cefonicid has the molecular formula C18H18N6O8S3 and a molecular weight of 542.56 g/mol.

Sources

• DrugCentral drug card 542 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201005 — compound record and bioactivity
• PubChem CID 43594 — chemical identifiers
• DrugBank DB01328 — drug record
• FDA UNII 6532B86WFG — substance identity
• DailyMed: FDA labels for Cefonicid — current prescribing information (label search)
• UniProt P14780 (MMP9) — target protein
• UniProt P35354 (PTGS2) — target protein
• UniProt P31391 (SSTR4) — target protein

How this page is built: methodology · editorial policy & corrections.